Mesenchymal stem cell‐based angiopoietin‐1 gene therapy for acute lung injury induced by lipopolysaccharide in mice
Authors:
- 11 December 2007
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 214 (4) , 472-481
Abstract
Bone marrow‐derived mesenchymal stem cells (MSCs) can serve as a vehicle for gene therapy. Angiopoietin‐1 (Ang1) is a critical factor for endothelial survival and vascular stabilization via the inhibition of endothelial permeability and leukocyte–endothelium interactions. We hypothesized that MSC‐based Ang1 gene therapy might be a potential therapeutic approach for lipopolysaccharide (LPS)‐induced lung injury. MSCs were isolated from 6 week‐old inbred male mice and transduced with the Ang1 gene, using a lentivirus vector. The MSCs showed no significant phenotypic changes after transduction. In the in vivo mouse model, the LPS‐induced lung injury was markedly alleviated in the group treated with MSCs carrying Ang1 (MSCs– Ang1 ), compared with groups treated with MSCs or Ang1 alone. The expression of Ang1 protein in the recipient lungs was increased after MSCs– Ang1 administration. The histopathological and biochemical indices of LPS‐induced lung injury were improved after MSCs‐based Ang1 gene treatment. MSCs– Ang1 administration also reduced pulmonary vascular endothelial permeability and the recruitment of inflammatory cells into the lung. Cells of MSC origin could be detected in the recipient lungs for 2 weeks after injection with MSCs. These results suggest that MSCs and Ang1 have a synergistic role in the treatment of LPS‐induced lung injury. MSC‐based Ang1 gene therapy may be developed as a potential novel strategy for the treatment of acute lung injury. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 41 references indexed in Scilit:
- Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung InjuryCirculation, 2005
- Protective Role of Angiopoietin-1 in Endotoxic ShockCirculation, 2005
- Transcriptional Profiling of Lipopolysaccharide-Induced Acute Lung InjuryInfection and Immunity, 2004
- Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosisProceedings of the National Academy of Sciences, 2004
- Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndromeThe Journal of Pathology, 2003
- Angiopoietin‐1 inhibits endothelial permeability, neutrophil adherence and IL‐8 productionBritish Journal of Pharmacology, 2003
- Future Research Directions in Acute Lung Injury: Summary of a National Heart, Lung, and Blood Institute Working GroupAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Angiopoietin‐1 negatively regulates expression and activity of tissue factor in endothelial cellsThe FASEB Journal, 2001
- Angiopoietin-1 Is an Antipermeability and Anti-Inflammatory Agent In Vitro and Targets Cell JunctionsCirculation Research, 2000
- Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression CloningCell, 1996